ALX Oncology (ALXO) vs Coherus Oncology (CHRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ALX Oncology (ALXO) has outperformed Coherus Oncology (CHRS) over the past year, losing 35.6% versus a loss of 39.2%. Over five years, CHRS leads with a -93.7% price change compared with -97.9% for ALXO. ALX Oncology is the larger company by market cap ($172.8 million vs $165.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | CHRS |
|---|---|---|
| Share price | $1.25 | $1.07 |
| Market cap | $172.85M | $165.32M |
| 1-day change | +5.93% | 0.00% |
| YTD return | +10.62% | -24.65% |
| 1-year return | -35.57% | -39.20% |
| 5-year return | -97.88% | -93.71% |
| EPS (TTM) | $-1.20 | $-1.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $2.62 |
| 52-week low | $1.05 | $0.974 |
| Distance from 52-week high | -53.01% | -59.10% |
| Analyst consensus | none | none |
| Avg. price target upside | +268.00% | +624.30% |
| Average volume | 1.04M | 1.16M |
| Shares outstanding | 138.28M | 154.50M |
| Employees | 48 | 144 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
ALXO vs CHRS FAQ
Which is bigger, ALX Oncology or Coherus Oncology?
ALX Oncology (ALXO) is larger, with a market capitalization of $172.85M compared with $165.32M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, ALXO or CHRS?
ALXO returned -35.57% over the past 12 months, compared with -39.20% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Coherus Oncology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ALX Oncology and Biotechnology: Biological Products (No Diagnostic Substances) for Coherus Oncology.